```html

Cutaneous Melanoma – A Comprehensive Medical Guide

Overview

Cutaneous melanoma is a malignant tumor that arises from melanocytes, the pigment‑producing cells in the skin. Although it accounts for only about 1–2 % of all skin cancers, it causes the majority of skin‑cancer‑related deaths because of its ability to spread (metastasize) to other organs.

Who it affects: Melanoma can develop at any age, but incidence peaks in people aged 40–70 years. It is more common in men than women after age 50, and in lighter‑skinned populations (Caucasians) due to lower melanin protection. However, it also occurs in people of all skin tones, particularly on less‑pigmented areas such as the soles of the feet in individuals with darker skin.

Prevalence: In the United States, the CDC reported ~106,000 new cases of melanoma in 2024, with an estimated 7,800 deaths. Worldwide, the WHO estimates 325,000 new cases and 57,000 deaths annually.

Symptoms

Melanoma frequently mimics benign moles, but certain characteristics raise concern. Use the ABCDE rule (and “E” for “Evolution”) to evaluate lesions. Below is a full symptom list.

Skin‑related signs

• Asymmetry: One half of the mole does not match the other.
• Border irregularity: Edges are scalloped, notched, or blurred.
• Color variation: Shades of tan, brown, black, sometimes white, red or blue.
• Diameter: Greater than 6 mm (about the size of a pencil eraser), though some melanomas are smaller.
• Evolution: Change in size, shape, color, elevation, or new symptoms (itching, bleeding, crusting).
• Elevation: Raised or nodular lesions, often feel firm.
• Ulceration or bleeding: Surface breaks down, leading to crusts or bleeding.
• Itching or tenderness: Unusual sensations in a formerly benign-appearing mole.
• New pigmented lesions after age 30, especially on the trunk (men) or legs (women).

Systemic signs (suggestive of metastasis)

• Unexplained weight loss.
• Persistent fatigue.
• Lymph node enlargement (often in the neck, armpit, or groin).
• Persistent cough or shortness of breath.
• Headaches, seizures, or neurological changes (possible brain involvement).

Causes and Risk Factors

Melanoma results from DNA damage in melanocytes. The damage is usually caused by ultraviolet (UV) radiation, but genetics and other factors also play a role.

Primary causes

• UV radiation: Both intermittent intense exposure (sunburns, tanning beds) and cumulative chronic exposure increase risk. UV‑B (280‑320 nm) is most carcinogenic.
• Genetic mutations: Sporadic mutations in the BRAF, NRAS, and c‑KIT genes drive many melanomas.

Risk factors

• Fair skin, red or blond hair, blue/green eyes: Less melanin = less natural UV protection.
• Numerous or atypical nevi (moles): >50 moles or dysplastic (atypical) moles significantly raise risk.
• Personal or family history of melanoma: 2‑fold higher risk if a first‑degree relative had it.
• History of severe sunburns, especially childhood: Increases risk 2‑3×.
• Use of indoor tanning devices: Up to 80 % higher risk; FDA classifies tanning beds as carcinogenic.
• Weakened immune system: Organ‑transplant recipients, HIV infection, or immunosuppressive medications.
• Genetic syndromes: CDKN2A (p16) mutations, xeroderma pigmentosum, familial atypical multiple mole melanoma (FAMMM) syndrome.
• Age and gender: Incidence rises after age 40; men have higher mortality after age 50.

Diagnosis

Early detection is critical. Diagnosis generally proceeds in three steps: clinical evaluation, biopsy, and staging.

Clinical evaluation

• Full skin examination: Dermatologist inspects the entire body, often using a dermatoscope (magnified, polarized light device).
• Photography and monitoring: Digital mole mapping tracks changes over time.

Biopsy techniques

• Excisional biopsy: Preferred method; entire lesion (including a margin of normal skin) is removed.
• Punch or incisional biopsy: Used when lesion is large or in a cosmetically sensitive area; a portion is sampled.
• Sentinel lymph node biopsy (SLNB): Performed when the primary tumor is >0.8 mm thickness or has ulceration, to assess microscopic spread to regional nodes.

Pathology and staging

Pathologists assess:

• Thickness (Breslow depth) – the most important prognostic factor.
• Ulceration, mitotic rate, and presence of tumor-infiltrating lymphocytes.
• Genetic mutation testing (BRAF, NRAS, KIT) to guide targeted therapy.

Staging follows the American Joint Committee on Cancer (AJCC) 8th Edition, incorporating tumor thickness (T), nodal involvement (N), and distant metastasis (M). Imaging (CT, MRI, PET/CT) is ordered for higher-stage disease.

Treatment Options

Treatment depends on stage, mutation profile, patient health, and personal preferences.

Localized disease (Stage 0‑I)

• Surgical excision: Wide local excision with 1‑2 cm margins (based on tumor thickness). Usually curative.
• Adjuvant therapy: May be considered for high‑risk lesions (e.g., >0.8 mm thickness, ulceration) – options include interferon‑α or approved checkpoint inhibitors in a clinical‑trial context.

Regional disease (Stage II‑III)

• Wide excision + sentinel lymph node biopsy: If nodes are positive, completion lymph‑node dissection (CLND) may be performed, though recent trials (MSLT‑II) support observation with ultrasound surveillance.
• Adjuvant systemic therapy:
  • Immune checkpoint inhibitors – nivolumab or pembrolizumab (PD‑1 blockers) improve recurrence‑free survival.
  • Targeted therapy – for BRAF‑mutant tumors, combined BRAF inhibitor (vemurafenib, dabrafenib) + MEK inhibitor (cobimetinib, trametinib).
  • Interferon‑α – less commonly used due to toxicity.

Distant metastatic disease (Stage IV)

• Immunotherapy: Nivolumab or pembrolizumab alone; combination ipilimumab (CTLA‑4 inhibitor) + nivolumab for higher response rates but increased adverse events.
• Targeted therapy: BRAF‑mutated melanoma – combined BRAF + MEK inhibition (e.g., dabrafenib + trametinib) yields response rates of 60‑70 %.
• Oncolytic virus therapy: Talimogene laherparepvec (T‑VEC) injected directly into accessible skin metastases.
• Radiation therapy: Palliative for brain or bone metastases; stereotactic radiosurgery (SRS) for isolated brain lesions.
• Surgical resection: Considered for isolated metastases when achievable.

Lifestyle and supportive care

• Smoking cessation – improves overall treatment tolerance.
• Nutrition: adequate protein, fruits, vegetables, and omega‑3 fatty acids can help maintain weight and immune function.
• Physical activity: regular moderate exercise (e.g., walking 150 min/week) improves fatigue and mood.
• Psychosocial support: counseling, support groups, and survivorship programs are essential.

Living with Cutaneous Melanoma

Long‑term management focuses on surveillance, skin health, and quality of life.

Follow‑up schedule

• Year 1‑2: Dermatology visit every 3‑6 months; full‑body skin exam and lymph‑node evaluation.
• Year 3‑5: Visits every 6‑12 months.
• After 5 years: Annual exams unless high‑risk features persist.
• Imaging (CT, PET) as directed by oncologist based on stage and symptoms.

Self‑examination

Perform a monthly skin self‑check using mirrors and, if possible, a family member’s help. Document any new or changing lesions with photos and bring them to appointments.

Skin protection strategies

• Broad‑spectrum sunscreen SPF 30+ applied 15 minutes before sun exposure; reapply every 2 hours.
• Wear protective clothing, wide‑brim hats, and UV‑blocking sunglasses.
• Avoid peak UV hours (10 am‑4 pm) when possible.
• Never use indoor tanning devices.

Managing treatment side effects

• Immunotherapy: Monitor for skin rash, colitis, hepatitis, endocrine abnormalities (thyroid, adrenal). Promptly report new symptoms.
• Targeted therapy: Watch for fever, joint pain, rash, and photosensitivity; maintain hydration.
• Use prescribed steroids or other medications under provider guidance to mitigate severe reactions.

Emotional well‑being

Fear of recurrence is common. Cognitive‑behavioral therapy, mindfulness meditation, and support groups (e.g., Melanoma Research Foundation) have demonstrated benefit in reducing anxiety and depression.

Prevention

Because UV exposure is modifiable, prevention can dramatically lower risk.

• Sun‑safe behaviors: Seek shade, wear UPF‑rated clothing, apply sunscreen liberally.
• Education: Teach children the ABCDE rule early; schools and community programs are effective platforms.
• Regular skin checks: Encourage yearly dermatologist visits, especially for individuals with >20 moles or personal/family history.
• Genetic counseling: For families with known CDKN2A or other high‑risk mutations, consider counseling and possibly earlier screening.
• Avoid tanning beds: State laws ban their use by minors; public health campaigns reinforce this.

Complications

If melanoma is not diagnosed or treated promptly, it can lead to serious complications.

• Local invasion: Destruction of underlying muscle, cartilage, or bone.
• Lymphatic spread: Enlarged, sometimes painful nodes; can cause lymphedema after node removal.
• Distant metastasis: Common sites include lungs, liver, brain, and bone; associated with organ failure.
• Secondary cancers: Patients treated with certain immunotherapies may develop autoimmune disorders.
• Psychological impact: Chronic anxiety, depression, and reduced quality of life.

When to Seek Emergency Care

References

1. Mayo Clinic. Melanoma – Symptoms & Causes. Updated 2023.
2. Centers for Disease Control and Prevention. Skin Cancer – Melanoma. 2024.
3. National Cancer Institute. Melanoma Treatment (PDQ®)–Patient Version. 2023.
4. Cleveland Clinic. Melanoma. Reviewed 2024.
5. World Health Organization. Melanoma of the Skin Fact Sheet. 2022.
6. Schadendorf D, et al. “Adjuvant Therapy for Melanoma: A Review of Current Options.” J Clin Oncol. 2022;40(14):1562‑1576.
7. American Cancer Society. Melanoma Skin Cancer. 2024.

```